Industry veterans Jill M.
Jene, Ph.D. and Spyros Papapetropoulos M.D. Ph.D.
appointed to Board
SALT
LAKE CITY, April 11, 2022 /PRNewswire/ -- Lipocine
Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on
neuroendocrine and metabolic disorders, announced today the
appointment of Jill M. Jene, Ph.D.
and Spyros Papapetropoulos, M.D., Ph.D. to its board of
directors.
"We are very pleased to welcome Jill
Jene and Spyros Papapetropoulos to our board of directors.
Each of them brings a wealth of relevant expertise," said
Mahesh V. Patel, Ph.D., Chairman and
CEO of Lipocine. "Jill brings extensive experience in
corporate development and portfolio strategy with a strong track
record in creating value through successful licensing and M&A
transactions. Spyros has a broad spectrum of medical and
development experience with specific expertise in neuroscience,
which we believe will be invaluable as we advance our innovative
programs, especially the neuroactive steroid ("NAS") programs. We
are confident that the insights and contributions of Jill and
Spyros will strengthen the Board and we are enthusiastic about the
role they can play in helping Lipocine succeed."
Jill M Jene, Ph.D. brings more than 20 years
of biopharmaceutical strategy, leadership and deal making
experience to the Company's Board of Directors. She has
amassed a deal sheet of over $6 billion of closed transactions
and she is currently the Founder and Principal of Jene Advisors, a
Biopharmaceutical advisory firm. Dr. Jene
was the Vice President and Head of Corporate Development,
Strategy, Portfolio Planning and Alliance Management at Adamas
until the company was sold to Supernus in November of
2021. Before joining Adamas, Dr. Jene was Vice President of
Business Development for PDL, a publicly traded biotechnology
company where she was responsible for executing deal-making to
maximize value for shareholders. Before PDL, Dr. Jene led Business
Development at twoXAR pharmaceuticals where she led deal-making,
resulting in closing 6 new partnerships and securing Series A
funding from Softbank and A16z. Prior to twoXAR, Dr. Jene was
at Depomed (now Assertio), where she led over 36 transactions
including licensing and M&A deals including acquiring 4
commercial franchises. Earlier in her career, she held positions of
increasing responsibility at Baxter International, the 3M Company (Pharmaceutical Division now part of
Valeant) and Cell Genesys (acquired by Biosante). Dr. Jene
earned a B.S. from Bradley, a M.S. and Ph.D. in Chemistry from
Northwestern University, and an M.B.A.
in strategic management from DePaul
University.
Spyros Papapetropoulos, M.D., Ph.D. is an experienced
biopharmaceutical executive, recognized neuroscientist and
neurodegenerative disease clinician. He is currently Chief Medical
Officer at Vigil Neurosciences Inc. where he oversees all the
clinical development and medical functions. Prior to Vigil, Dr.
Papapetropoulos served as SVP, Head of Development (CDO) at Acadia
Pharmaceuticals Inc., CEO at SwanBio Therapeutics, and Head of
Research & Development and Chief Medical Officer at Cavion.
Before Cavion, he held senior/executive positions at Biogen Inc.,
Allergan plc, Pfizer Inc., and Teva Pharmaceuticals Inc. Dr.
Papapetropoulos has overseen a broad spectrum of biopharmaceutical
development programs including small molecules, biologics, and gene
therapy leading to successful regulatory filings and new product
launches worldwide. He holds an appointment as consultant with
Massachusetts General Hospital and has been involved in
groundbreaking research that led to the characterization of genetic
forms of Parkinson's disease and development of methodologies that
revolutionized the quantification of neuromotor function in
clinical research settings. Dr. Papapetropoulos has published more
than 170 peer reviewed articles and authored several book chapters
and patents. He received an M.D. from Semmelweis University
in Budapest, Hungary and an M.D.,
Ph.D. from the University of Patras in Greece.
About Lipocine
Lipocine Inc. is a biopharmaceutical company focused on
neuroendocrine and metabolic disorders using its proprietary drug
delivery technologies. Lipocine's clinical development pipeline
includes: LPCN 1148, LPCN 1144, LPCN 1111, LPCN 1107 and oral
neuroactive steroids including LPCN 1154 and LPCN 2101. TLANDO, a
novel oral prodrug of testosterone containing testosterone
undecanoate, is approved by the FDA for conditions associated with
a deficiency of endogenous testosterone, also known as
hypogonadism, in adult males. LPCN 1148 is an oral prodrug of
bioidentical testosterone targeted for the management of symptoms
associated with liver cirrhosis. LPCN 1144, an oral prodrug
of bioidentical testosterone, recently completed a Phase 2 clinical
study demonstrating potential utility in the treatment of
non-cirrhotic NASH. LPCN 1111, a novel oral prodrug of
testosterone, originated and is being developed by Lipocine as a
next-generation oral testosterone product with potential for
once-daily dosing. In a phase 2 clinical evaluation when
administered as once or twice daily, LPCN 1111 met primary and
secondary endpoints. LPCN 1107 is potentially the first oral
hydroxyprogesterone caproate product candidate indicated for the
prevention of recurrent preterm birth and has been granted orphan
drug designation by the FDA. Neuroactive steroids are
currently being evaluated including LPCN 1154 for the potential
treatment of postpartum depression and LPCN 2101 for the potential
treatment of epilepsy. For more information, please visit
www.lipocine.com.
Forward-Looking
Statements
This release contains "forward-looking statements" that are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995 and include statements that are not
historical facts regarding Lipocine's product candidates and
related clinical trials, the timing of completion of clinical
trials, the timing and completion of regulatory reviews, outcomes
of clinical trials of our product candidates, the potential uses
and benefits of our product candidates, and our product development
efforts. Investors are cautioned that all such forward-looking
statements involve risks and uncertainties, including, without
limitation, the risks that the FDA will not approve any of our
products, risks related to our products, expected product benefits
not being realized, clinical and regulatory expectations and plans
not being realized, new regulatory developments and requirements,
risks related to the FDA approval process including the receipt of
regulatory approvals, the results and timing of clinical trials,
patient acceptance of Lipocine's products, the manufacturing and
commercialization of Lipocine's products, and other risks detailed
in Lipocine's filings with the SEC, including, without limitation,
its Form 10-K and other reports on Forms 8-K and 10-Q, all of which
can be obtained on the SEC website at www.sec.gov. Lipocine
assumes no obligation to update or revise publicly any
forward-looking statements contained in this release, except as
required by law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lipocine-announces-board-of-director-appointments-301521263.html
SOURCE Lipocine Inc.